These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 32841168)

  • 1. Combining clinical features and MEST-C score in IgA nephropathy may be a better determinant of kidney survival.
    Yeter HH; Gonul I; Guz G; Helvaci O; Korucu B; Akcay OF; Derici U; Arinsoy T
    Rom J Intern Med; 2020 Dec; 58(4):209-218. PubMed ID: 32841168
    [No Abstract]   [Full Text] [Related]  

  • 2. The use of the Oxford classification of IgA nephropathy to predict renal survival.
    Alamartine E; Sauron C; Laurent B; Sury A; Seffert A; Mariat C
    Clin J Am Soc Nephrol; 2011 Oct; 6(10):2384-8. PubMed ID: 21885791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. To evaluate the utility of Oxford classification in predicting renal outcome in IgA nephropathy patients.
    Saleem N; Nasir H; Anwar F; Aziz M; Khurshid K; Bashir S; Khan A
    Int Urol Nephrol; 2024 Jan; 56(1):345-353. PubMed ID: 37378850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is it possible to predict the evolution of IgAN? Validation of the IgA nephropathy progression calculator and its relationship with MEST-C score in our population.
    Martín-Penagos L; Benito A; Oviedo MV; López Del Moral Cuesta C; Martín López J; Gómez Román J; López-Mejías R; Fernandez-Fresnedo G; Ruíz San Millán JC; Rodrigo Calabia E
    Nefrologia (Engl Ed); 2019; 39(5):523-530. PubMed ID: 30902505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MEST C Score and Treatment Response in IgA Nephropathy in a Tertiary Care Hospital: A Descriptive Cross-sectional Study.
    Thapa S; Sigdel MR
    JNMA J Nepal Med Assoc; 2024 Jul; 62(276):536-541. PubMed ID: 39369400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measures of Urinary Protein and Albumin in the Prediction of Progression of IgA Nephropathy.
    Zhao YF; Zhu L; Liu LJ; Shi SF; Lv JC; Zhang H
    Clin J Am Soc Nephrol; 2016 Jun; 11(6):947-955. PubMed ID: 27026518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between blood neutrophil-lymphocyte ratio and renal tubular atrophy/interstitial fibrosis in IgA nephropathy patients.
    Chai L; Cai K; Wang K; Luo Q
    J Clin Lab Anal; 2021 Jun; 35(6):e23774. PubMed ID: 33951240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Profile, Histopathological Features and Outcome of IgA Nephropathy in a Tertiary Care Hospital in India.
    Jha VK; Mahapatra D; Jairam A
    Saudi J Kidney Dis Transpl; 2020; 31(5):1091-1100. PubMed ID: 33229774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical importance of the updated Oxford classification in allograft IgA nephropathy.
    Park S; Go H; Baek CH; Kim YH; Kim YC; Yang SH; Lee JP; Min SI; Ha J; Song EY; Kim YS; Park SK; Lee H; Moon KC
    Am J Transplant; 2019 Oct; 19(10):2855-2864. PubMed ID: 31017369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of ESRD in IgA Nephropathy Patients from an Asian Cohort: A Random Forest Model.
    Liu Y; Zhang Y; Liu D; Tan X; Tang X; Zhang F; Xia M; Chen G; He L; Zhou L; Zhu X; Liu H
    Kidney Blood Press Res; 2018; 43(6):1852-1864. PubMed ID: 30537719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the Haas and the Oxford classifications for prediction of renal outcome in patients with IgA nephropathy.
    Park KS; Han SH; Kie JH; Nam KH; Lee MJ; Lim BJ; Kwon YE; Kim YL; An SY; Kim CH; Doh FM; Koo HM; Oh HJ; Kang SW; Choi KH; Jeong HJ; Yoo TH
    Hum Pathol; 2014 Feb; 45(2):236-43. PubMed ID: 24439222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utilizing the MEST score for prognostic staging in IgA nephropathy.
    Haaskjold YL; Bjørneklett R; Bostad L; Bostad LS; Lura NG; Knoop T
    BMC Nephrol; 2022 Jan; 23(1):26. PubMed ID: 35016634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and histopathologic profile of patients with primary IgA nephropathy seen in a tertiary hospital in India.
    Bagchi S; Singh G; Yadav R; Kalaivani M; Mahajan S; Bhowmik D; Dinda A; Agarwal SK
    Ren Fail; 2016; 38(3):431-6. PubMed ID: 26837482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Oxford classification as a predictor of prognosis in patients with IgA nephropathy.
    Kang SH; Choi SR; Park HS; Lee JY; Sun IO; Hwang HS; Chung BH; Park CW; Yang CW; Kim YS; Choi YJ; Choi BS
    Nephrol Dial Transplant; 2012 Jan; 27(1):252-8. PubMed ID: 21606384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A validation study of crescents in predicting ESRD in patients with IgA nephropathy.
    Zhang X; Shi S; Ouyang Y; Yang M; Shi M; Pan X; Lv J; Wang Z; Ren H; Shen P; Wang W; Zhang H; Xie J; Chen N
    J Transl Med; 2018 May; 16(1):115. PubMed ID: 29724226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The MEST score provides earlier risk prediction in lgA nephropathy.
    Barbour SJ; Espino-Hernandez G; Reich HN; Coppo R; Roberts IS; Feehally J; Herzenberg AM; Cattran DC; ;
    Kidney Int; 2016 Jan; 89(1):167-75. PubMed ID: 26759049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for progression in children and young adults with IgA nephropathy: an analysis of 261 cases from the VALIGA European cohort.
    Coppo R; Lofaro D; Camilla RR; Bellur S; Cattran D; Cook HT; Roberts IS; Peruzzi L; Amore A; Emma F; Fuiano L; Berg U; Topaloglu R; Bilginer Y; Gesualdo L; Polci R; Mizerska-Wasiak M; Caliskan Y; Lundberg S; Cancarini G; Geddes C; Wetzels J; Wiecek A; Durlik M; Cusinato S; Rollino C; Maggio M; Praga M; K Smerud H; Tesar V; Maixnerova D; Barratt J; Papalia T; Bonofiglio R; Mazzucco G; Giannakakis C; Soderberg M; Orhan D; Di Palma AM; Maldyk J; Ozluk Y; Sudelin B; Tardanico R; Kipgen D; Steenbergen E; Karkoszka H; Perkowska-Ptasinska A; Ferrario F; Gutierrez E; Honsova E
    Pediatr Nephrol; 2017 Jan; 32(1):139-150. PubMed ID: 27557557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors of progressive IgA nephropathy which progress to end stage renal disease within ten years: a case-control study.
    Shu D; Xu F; Su Z; Zhang J; Chen C; Zhang J; Ding X; Lv Y; Lin H; Huang P
    BMC Nephrol; 2017 Jan; 18(1):11. PubMed ID: 28061828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors and therapy assessment of IgA nephropathy: report from a single unit in iran.
    Soleymanian T; Najafi I; Salimi BH; Broomand B
    Ren Fail; 2011; 33(6):572-7. PubMed ID: 21663387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of the Oxford classification and the Oxford score in IgA nephropathy: A Tunisian study.
    Jebali H; Ghabi H; Mami I; Kaab BB; Fatma LB; Smaoui W; Haouet S; Mahjouba HB; Hassan M; Hmida FB; Raies L; Zouaghi MK
    Saudi J Kidney Dis Transpl; 2020; 31(6):1366-1375. PubMed ID: 33565449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.